<code id='CC1C43C650'></code><style id='CC1C43C650'></style>

<acronym id='CC1C43C650'></acronym>

<center id='CC1C43C650'><center id='CC1C43C650'><tfoot id='CC1C43C650'></tfoot></center><abbr id='CC1C43C650'><dir id='CC1C43C650'><tfoot id='CC1C43C650'></tfoot><noframes id='CC1C43C650'>

<optgroup id='CC1C43C650'><strike id='CC1C43C650'><sup id='CC1C43C650'></sup></strike><code id='CC1C43C650'></code></optgroup>

<b id='CC1C43C650'><label id='CC1C43C650'><select id='CC1C43C650'><dt id='CC1C43C650'><span id='CC1C43C650'></span></dt></select></label></b><u id='CC1C43C650'></u>

~~<i id='CC1C43C650'><strike id='CC1C43C650'><tt id='CC1C43C650'><pre id='CC1C43C650'></pre></tt></strike></i>~~

Home» explore» focus

focus

focus

author：Wikipedia 2025-10-06 13:33:15 Page View：7868

Calling Bullshit course University of Washington — Screenshot via callingbullshit.org

Tired of alternative facts, fake news, and breathless hyperbole, two professors at the University of Washington are trying to strike a blow for science.

Their weapon? A new course: “Calling Bullshit In the Age of Big Data.”

advertisement

The class website and colorful syllabus went online last month and almost instantly went viral.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sanofi says it has 12 blockbusters on the way. Will investors believe it?
Next article： Sports medicine is finally prioritizing gender equality

focus

In age of alternative facts, a scholarly course on calling out crap

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Leukemia patients are helped by Syndax's new type of therapy

Leukemia patients are helped by Syndax's new type of therapy

AdobeSANDIEGO—OneofthetoughestsubtypesofacuteleukemiainvolvesageneticalterationintheKMT2Agene.Manyca

Moonlake's readout produced a cash windfall. Risks remain

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

RubyWallauforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

read more